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vous system, heart, breast and other organs. Indepen-
dent studies described a ligand for the oncogene ErbB2 
(neu, Her2) and factors that stimulated proliferation of 
Schwann cells, as well as synthesis of receptors for acetyl-
choline by muscle. These ligands and factors are essential-
ly products of the same gene, referred to by Marchionni 
M. as neuregulin (NRG-1) [1]. Besides NRG-1 gene, there 
are other genes that encode related proteins, such as 
NRG-2 (Don-1, NTAK), NRG-3 and NRG-4. There are few 
studies that describe NRG-2, -3 and -4 and a complete 
analysis of their function remains a challenge. However, 
NRG-2 was recently reported as a component of stress 
granules (SG), microscopically visible aggregates of trans-
lationally stalled messenger ribonucleoprotein complex-
es that are formed in response to direct stress conditions 
[2]. Furthermore, it was shown that NRG-2, secreted from 
astrocytes, bound to ErbB3 on neurons and promoted 
neuronal survival [3]. NRG-3 was shown to be associat-
ed with schizophrenia (SZ) in a Chinese population [4], 
with bipolar disorder (BD) [5] and with the risk and age 
of onset of Alzheimer disease (AD) [6]. In addition, NRG-3 
has a key function in promoting early mammary morpho-
genesis and is involved in breast cancer (BC) [7]. NRG-4 
expression was decreased in human inflammatory bowel 
disease samples and mouse models of colitis, suggesting 
that activation of ErbB4 is altered [8]. An interesting study 
[9] showed that NRG-4 overexpression prevents high fat 
diet-induced weight gain and fatty liver and reduces obe-
sity-induced chronic inflammation.
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Introduction
The neuregulins
Neuregulins, a family of EGF-like signaling molecules, 
are involved in cell-cell crosstalk and play an important 
role in development, maintenance and repair of the ner-
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Considering the increasing interest and research fo-
cused on NRG-1 in the past years, this review summariz-
es what is currently known about NRG-1 and its impact 
on health and disease as well as its current and poten-
tial use(s) as a CNS anti-inflammatory agent against in-
ducers of brain inflammation and injury as well as in the 
treatment of various neurological disorders.
Neuregulin-1: Structure, function and signaling 
pathways: NRG-1 gene encodes 21 exons located on hu-
man chromosome 8p22-21. Alternative splicing of more 
than 30 exons in different parts of the NRG-1 transcript 
generates more than 30 isoforms that can be grouped 
into six types (I-VI) [10-12] (Figure 1). They are synthe-
sized as transmembrane precursors consisting of either 
an immunoglobulin-like (Ig) domain or cysteine-rich do-
main (CRD), an EGF-like domain, a transmembrane do-
main and a cytoplasmic tail [13]. NRG-1 types I and II 
are released from the cell surface after protease-medi-
ated proteolytic cleavage and may function as paracrine 
signals [14]. NRG-1 type III remains tethered to the cell 
membrane after cleavage and acts as a juxtacrine sig-
nal [15]. Full-length type IV spans 1.8 kb and encodes 
a putative protein of 590 amino acids with a predicted 
molecular mass of approximately 66 kDa [15]. Further-
more, there are two major classes of NRG-1 identified as 
α and β isoforms. NRG-1α and NRG-1β contain related, 
but structurally distinct EGF-like domains composed of 
a common amino terminal segment followed by α or β 
variant sequences [16]. NRG-1β isoforms predominate 
in the nervous system while α isoforms are common in 
mesenchymal cells and are critically important for breast 
development [14]. Type I NRGα and β isoforms are the 
predominant isoforms expressed in early embryogene-
sis, whereas type II and type III are undetectable until 
the mid-gestation stage [17]. Type I or Heregulin is an 
acetylcholine receptor activator, type II is a Glial Growth 
Factor, type III is a sensory and motor neuron-derived 
factor and type IV is involved in neuronal activity regula-
tion. Functions of types V and VI are not well known and 
their investigation remains a challenge. Types I, II and III 
of NRG-1 express in human peripheral blood in addition 
to neurons, while types IV and V express specifically in 
the brain [18].
Neuregulins transmit their signals to target cells by 
interacting with transmembrane tyrosine kinase recep-
tors of the ErbB (HER) family (Figure 1) [19]. This family 
includes four members of the epidermal growth factor 
receptor (EGF-R, ErbB1, ErbB2, ErbB3, and ErbB4). Re-
ceptor-ligand interaction induces the heterodimeriza-
tion of receptor monomers, which in turn results in 
the activation of intracellular signaling cascades and 
the induction of cellular responses. In vivo, functional 
NRG-1 receptors are heterodimers composed of ErbB2 
with either an ErbB3, or ErbB4 molecule [20]. This in-
teraction activates various signaling pathways including 
the mitogen-activated protein (MAP) kinases and phos-
phatidyl-inositol-3-kinase PI3-K/Akt survival pathways 
[21,22]. NRG-1 effects are associated with the regula-
tion of both canonical and alternative NF-kB signaling 
pathways [23]. Increased cardiac mechanical stress 
leads to upregulation of NRG-1. Interestingly, integrins, 
a family of receptors expressed on cardiomyocytes, act 
as sensors for mechanical stress and can non-canonical-
ly bind NRG-1 [24]. NRG-1 regulates cell maintenance, 
Figure 1: Neuregulin (NRG) and  ErbB receptor structures. NRG gene products share a structural characteristic for the ex-
tracellular epidermal growth factor (EGF) domain and it differentiates this subfamily from other members of the EGF family. 
All EGF family members are ligands of ErbB receptors, although with varying affinities, with ErbB3 and ErbB4 being specific 
NRG-binding receptors. NRG-1 isoforms have been classified in types I-VI on the basis of differences in the NH2-terminal distal 
region [19].
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ferential expression of NRG-1 and its ErbB receptors in 
gastrointestinal structures, and found higher expres-
sion levels in stomach and small intestine [35]. All these 
models assessed the complex involvement of NRG-1 in 
development and in adult life, although many aspects 
need further investigation.
Neuregulin-1 in Disease
Cardiovascular disorders
During embryogenesis, NRG-1 expression leads to 
cardiomyocyte proliferation. Studies found that there 
is an interaction between hyaluronan and Erb signaling 
during endocardium development [39]. NRG and Notch1 
are necessary for the development of the atrioventric-
ular conduction system [40]. In the adult heart, NRG-1 
is located in endothelial cells, playing an important role 
in regulation of survival, hypertrophy, proliferation and 
interaction between cardiomyocytes [41]. Furthermore, 
NRG-1 provides protection against apoptosis, myofibril-
lar disarray, anthracycline-induced cardiomyopathy, 
and scar formation [42]. These data underline the im-
portance of NRG-1 in cardiovascular development, as 
well as in cardiac maintenance during the adult life.
Many studies have shown the protective effects of 
NRG-1 in heart disease. Administration of NRG-1 im-
proved cardiac function via SERCA2a (Sarco/Endoplas-
mic Reticulum Ca2+ ATPase 2a) and cMLCK (Cardiac My-
osin Light Chain Kinase) in a rat heart failure model [43] 
and significantly enhanced cardiac function in patients 
with chronic heart failure [44]. Furthermore, NRG-1β 
treatment leads to iPSC (induced pluripotent cell) dif-
ferentiation into ventricular-like cardiac cells, which are 
of preserving cardiac function and tissue viability when 
transplanted in a mouse model of acute myocardial in-
farction [45]. NRG-1 and ErbB receptors are expressed 
in ex vivo skeletal muscle vascular endothelial cells; the 
addition of NRG-1 induces angiogenesis [46]. Further-
more, elevated expression of NRG-1 increased the num-
ber of microvessels formed in the ischemic myocardium 
[47]. Although NRG-1 plays an important role in cardi-
ac development and in tissue recovery following heart 
ischemia, potentially including it in adjunctive therapy in 
the treatment of cardiac diseases remains a challenge.
Cancer
In head and neck cancer, tumor cells control the 
amount of cell-surface NRG-1 available for cleavage 
and ErbB3 activation [48]. Constitutively active forms of 
HER/ErbB receptors have been reported in tumors and 
their activation may occur through their overexpression 
in the plasma membrane or through their structural 
alterations [49]. In the invasive mucinous adenocarci-
noma of the lung, molecular lesions of the NRG-1 gene 
leads to aberrant activation of ErbB2/ErbB3 signaling 
[50]. NRG-1 treatment induced cancer stem cell (CSC) 
characteristics in breast cancer (BC) cell lines in vitro 
[51]. Furthermore, NRG-1 produced by BC cells can 
differentiation, proliferation, migration, and survival or 
apoptosis in neuronal and non-neuronal cell types [11].
Many cell types express NRG-1, including mi- croglial 
and neuronal cells, in response to several stimuli such as 
tissue injury, blood brain barrier (BBB) dysfunction and 
neuronal cell damage [25]. NRG-1 has anti-inflammatory 
properties. For example, recombinant human NRG-
1 decreases the production of superoxide and nitrite 
by stimulating mouse brain N9 microglial cells [26]. 
Furthermore, NRG-1 treatment in a cerebral ischemia 
model induced a decrease in microglial activation and 
IL-1 mRNA expression. NRG-1 reduced the expression 
of inflammatory genes associated with leukocyte 
migration and activation [27]. In contrast, early NRG-1 
mutations induced defects in the developing nervous 
system and embryos died in utero due to cardiovascular 
failure.
Neuregulin in Invertebrate and Vertebrate Mod-
els
In Drosophila central nervous system (CNS), neu-
ronal-glia interactions are necessary for the formation 
of the longitudinal axon trajectories. The protein Vein, 
found in drosophila, is similar in structure to NRG and 
is produced by neurons and leads to the survival of glia 
[28]. In Caenorhabditis elegans, a simple version of the 
NRG-ErbB is found, with a single receptor, the product 
of the let-23 gene and a single ligand encoded by lin-3 
[1]. An interesting study developed in fish showed that 
NRG-1 is found in the axolotl (Ambystoma mexicanum) 
peripheral nervous system and blastema and is capable 
of regeneration of amputated limbs, to the point of digit 
formation [29]. In a zebrafish model, which is hypoxia 
tolerant, NRG-1 plays a role in establishing the cardi-
ac nervous plexus, while inadequate innervation leads 
to deficits in cardiac maturation, function and survival 
[30]. Although flies, worms and fish have been used to 
understand the functions of simple conserved signaling 
systems, like the EGF/ErbB pathway, studies in inverte-
brates have been limited and challenging. Analysis of 
functions are limited due to the diversification of their 
corresponding ligands and receptor molecules, unlike 
in higher organisms [31]. NRG-1 is highly expressed 
in the developing brain and remains expressed in the 
adult nervous system [32]. Studies in heterozygous 
NRG-1 knockout mice showed that the animals exhibit 
impairments in prepulse inhibition and working memo-
ry [33]. However, an interesting study using transgenic 
mice overexpressing NRG-1 showed that aberrant hy-
per-signals of NRG-1 also disrupt various cognitive and 
behavioral processes, but further experiments are nec-
essary to clarify these observations [34]. In a rat model, 
hypothalamic NRG-1 was transported to the posterior 
pituitary as the β form. Thus, NRG-1β may function via 
the regulation of prolactin expression through a para-
crine mechanism [35-38]. In addition, a NRG-1 study in 
non-human primate rhesus monkey assessed the dif-
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Neurological disorders
Cerebrovascular diseases: Stroke, transient isch-
emic attack and intracerebral hemorrhage are cerebro-
vascular diseases which affect blood supply to the brain 
[15]. The lack of blood flow during a stroke leads to a 
complex pathophysiological response, resulting in neu-
ral injury. The mechanisms that lead to neural cell loss 
and injury include cytotoxicity, free radical release and 
inflammatory changes [18]. The inflammatory response 
enhances the ischemic injury, but also promotes recov-
ery. Following a stroke, immune cells release proinflam-
matory cytokines and free radicals which increase the 
inflammatory response and contribute to the neuronal 
injury post ischemia [18]. Treatment failure may be due 
to the intricate pathophysiological response to ischemic 
injury. Targeting multiple molecules in this pathway re-
mains a treatment challenge.
During ischemic brain injury, NRG-1 provides neuro-
protection. This effect, demonstrated by in vitro and in 
vivo models, is achieved through NRG-1’s stimulation 
of the PI3-kinase/Akt pathway. Oxygen glucose depri-
vation (OGD) is an in vitro method used to stimulate 
neuronal cell injury and imitates the pattern that occurs 
following ischemic injury in vivo [64]. Rat B35 neurons 
subjected to (OGD)/reoxygenation were treated with 
NRG-1 and showed significant increases in neuronal sur-
vival [65]. Different concentrations of NRG-1 added to 
neuronal culture at reoxygenation induced protection 
against OGD-induced neuronal apoptosis [66]. These 
data show that NRG-1 reduced cell death following 
OGD in a dose-dependent manner, by activating ErbB4 
receptors and GABAergic transmission [23]. Injury to 
oligodendrocyte progenitor cells (OPCs) caused by hy-
poxia plays a crucial role in white matter injury. A study 
observed NRG-1’s potential to influence the survival of 
OPCs damaged by OGD. OPCs were exposed to OGD, 
then treated with NRG-1 and the results showed that 
NRG-1 inhibited OGD-induced apoptosis and increased 
the survival rate of OPCs [67].
In vivo, NRG-1’s neuroprotective capabilities were 
tested via permanent middle cerebral artery occlusion 
(pMCAO) in an ischemic rat model. NRG-1 treatment 
prior to pMCAO significantly decreased infarction vol-
ume. MK-801, a N-methyl-D-aspartate (NMDA) recep-
tor antagonist, shows similar outcomes to NRG -1 treat-
ment, reducing neuronal death [67]. Co-administration 
of NRG-1 and MK-801 showed synergistic effects on 
the reduction of infarct following pMCAO. These find-
ings indicate that NRG-1 has the capability of inhibiting 
neuronal damage in rat pMCAO models and that com-
bination treatment of NRG-1 with MK-801 enhance the 
neuroprotective effects. In transient middle cerebral 
artery occlusion (tMCAO) model, NRG-1 given prior or 
13.5 hours after the onset of ischemia in rats reduced 
cortical damage and improved neurological outcomes 
[68]. Current treatment of stroke relies on TPA, which is 
enhance transendothelial migration and intravasation, 
due to induction of jagged-1 (JAG1), an important com-
ponent of the Notch pathway [52]. In BC, NRG-1-depen-
dent activation of HER3 induces primary resistance to 
trastuzumab in HER2- [53] overexpressing breast cancer 
cells [54]. In gastric tumors, fibroblasts secreted NRG-
1, which in turn increased the stem cells self-renewal 
and its overexpression was correlated with gastric can-
cer prognosis [55]. NRG-1 was demonstrated to be a 
prominent growth factor during cultivation of spheroids 
in vitro from non-small cell lung cancer specimens and 
pleural effusion [53]. Another study showed that ele-
vated levels of ErbB3 on ovarian cancer cells and cor-
responding ligand NRG-1 in the omentum allowed for 
tumor cell metastasis and growth in the omentum [56]. 
Although it has been demonstrated that NRG-1 induces 
tumor growth, stem cell characteristics, metastasis and 
chemo resistance, an engineered bivalent NRG-1β (NN) 
could protect against cardiotoxicity in cancer patients 
treated with doxorubicin [57]. Studies on circumstances 
under which NRG-1 functions to enhance regeneration 
and tissue repair and enhancement of tumor cell growth 
are urgently needed to elucidate the multidimensional 
aspects of its functional role in health and disease.
Neuromuscular disease and development
Neuromuscular disorders refer to diseases of the 
nerves that control muscles and communication be-
tween nerves and muscles [58]. Myelin plays an es-
sential role in accurate neuromuscular communication 
and conduction of electrical impulses by axons in both 
the central nervous system (CNS) and peripheral ner-
vous system (PNS). PNS myelin development depends 
on axonal signals which are provided by NRG1/ErbB 
receptors [59]. Similarly, NRG-1 plays a significant role 
in Hirchsprung disease, in which mutations in NRG-1 
gene can lead to absence of ganglion cells along the in-
testines, leading to obstruction of bowel function [60]. 
These ganglion cells are part of the enteric nervous sys-
tem (ENS), for which studies have shown that NRG-1 
also plays an important role in [61,62].
During embryonic development, the formation of 
muscular tissue is carried out through a process known 
as myogenesis. Recently, it was shown that NRG-1β 
plays a protective role to improve impaired myogenesis 
through PPARγ activation and transcriptional activity of 
NF-κB [63]. This was the first insight into the function 
of NRG-1β in regulating PPARγ/NF-κB signaling during 
myogenesis using an in vitro whole serum-based sepsis 
model.
Understanding of this process is essential for de-
signing future approaches for the treatment of skeletal 
muscle diseases and the prevention of or recovery from 
muscle loss in situations such as cachexia, muscle wast-
ing, sarcopenia and other neuromuscular degenerative 
diseases. 
ISSN: 2469-5866DOI: 10.23937/2469-5866/1410024
Cespedes et al. Int J Brain Disord Treat 2018, 4:024 • Page 5 of 13 •
cognitive disorders. NRG-1 plays an important role in 
brain plasticity and development. Moreover, NRG-1 has 
been found in multiple regions of the adult brain and 
is involved in the regulation of neurotransmission [79]. 
ND occurs in individuals with neurodevelopment prob-
lems and limited plasticity. In vivo studies using mouse 
models have focused on increasing and decreasing the 
NRG-1 and ErbB network levels. Results showed many 
behavioral deficits that suggested modified signaling 
intensity, which corresponds to a pathophysiological 
mechanism of psychosis and ND [80]. Inflammation can 
be defined as a part of the immune response that oc-
curs after a type of physical injury or microbial invasion 
[81]. Research suggests that inflammation may play an 
important role in cognitive disorders and needs to be 
studied in greater detail in ND patients [82].
The main ND that present a correlation with inflam-
mation and NRG-1 are Schizophrenia (SZ), Bipolar Dis-
order (BD), and Alzheimer’s Disease (AD). Evidence for 
increased inflammation has been found in a study that 
included 3,952 adolescents diagnosed with BD, Autism 
Spectrum Disorder (ASD), and SZ. Proinflammatory 
markers (PIMs) were measured and showed to be ele-
vated in those diagnosed with ND. However, this study 
suggested that future research is needed, using a larger 
population with one specific diagnosis [76].
SZ is an extremely debilitating disorder that has af-
flicts about 1% of the population [11]. Symptoms of this 
disorder include a misinterpretation of reality, halluci-
nations, disordered thinking, and an overall impairment 
of daily functioning that results from behavior changes. 
NRG-1 has been one of the most extensively studied 
genes in SZ [80]. One study conducted in 2017 exam-
ined the levels of NRG-1 and EGF in treatment-resistant 
schizophrenic patients and found decreased or abnor-
mally expressed levels of these proteins [79]. While past 
research has examined the levels of NRG-1 in the brain 
[83], future research could look toward understanding 
the mechanisms regulating NRG-1 expression and func-
tion and possible use of NRG-1 as a treatment for ND 
disorders. NRG-1 has also been used to suppress the 
induction and the expression of long-term potentiation 
in the hippocampus. In another mutant mice study, 
looking at the influence of NRG-1 and ErbB4, research-
ers observed a trend of loss of function in specific genes 
that specifically show to be risk factors for SZ [11]. This 
finding raises the question of a possible disease-related 
pathophysiological significance, perhaps inflammation. 
A study conducted on a group of post-mortem human 
schizophrenic brains have shown differential expression 
of NRG-1 mRNA and protein in many different regions 
of the brain, most notably seen in dorsolateral prefron-
tal cortex and the hippocampus [79]. This differential 
expression of these pathways suggests that NRG-1 is an 
interesting target to examine for SZ research.
In BD, individuals have an impairment of multiple 
focused on reducing infarct and inflammation associat-
ed with the infarct. 
Brain trauma: Traumatic brain injury (TBI) physical 
symptoms include loss of consciousness, headache, 
fatigue and dizziness. The cognitive symptoms include 
mood swings, memory or concentration problems, and 
feelings of depression or anxiousness. Earlier studies 
showed that administration of NRG-1 prior to brain 
trauma in a mouse model improved retention of spa-
tial memory, suggesting that NRG-1 may improve some 
functional outcomes after brain injury [69]. Often, BBB 
disruption occurs following TBI, leading to brain ede-
ma, inflammation, and neuronal death. BBB compro-
mised integrity exposes the brain tissue to substances 
that are present in blood vessels and it disrupts the 
ionic gradients necessary for proper neuronal function, 
which may lead to acute and long-term CNS dysfunc-
tion [70]. Studies suggest that NRG-1 has beneficial ef-
fects on endothelial permeability and BBB permeability 
following experimental trauma in mice and may have 
neuroprotective potential during CNS injury [71]. Along 
with injuring neurons, brain trauma also damages the 
axons, often resulting in diffuse axonal injury. Axonal in-
jury is one of the most important pathological features 
following TBI [41]. NRG-1 plays an integral role in axon 
physiology by influencing the survival and migration of 
Schwann cell precursors as well as remyelination and 
functional recovery after injury [42]. In an animal model 
of spinal cord injury, exogenously administered NRG-1 
enhanced the proliferation and differentiation of spinal 
neural precursor cells into oligodendrocytes, enhanced 
axonal preservation, and decreased astrogliosis and 
tissue degeneration [43]. Using a severe sciatic nerve 
injury model, a study has shown that in NRG-1 mutant 
mice, axons remyelination was impaired for 2 months 
after the nerve transection and anastomosis. However, 
by 3 months post-injury, the axons returned to normal. 
These data suggest that NRG-1 promotes nerve repair in 
the early phases of injury [72]. NRG-1 also induced bone 
pain-like behavior in rats by induction of and activation 
of ErbB2, Akt-1 and p38MAPK, which could be blocked 
by ErbB2 inhibitor [73]. The mechanisms involved in 
nerve repair in the late phases of injury remain to be 
investigated.
Neuropsychiatric disorders: Neuropsychiatric Disor-
ders (ND) affects around 450 million people worldwide. 
Those inflicted by these diseases tend to have memory, 
pattern separation, and reward processing problems 
[74-76]. ND impairs executive functioning, emotional 
regulation, and social facilitation. These neurobehavior-
al functions occur because of circuits that reside in the 
prefrontal cortex [77]. By 2020, it is predicted that ND 
will be the second highest cause of global disease bur-
den [78].
Studies are recently investigating the pivotal role 
of NRG-1 and inflammation in the development of the 
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tions and delusions, it has been hypothesized that the 
presence of NRG-1 may interact with specific inflam-
matory pathological processes that have been shown 
to be associated with Late Onset Alzheimer’s Dementia 
(LOAD) [85]. Furthermore, a study suggests that NRG1 
plays a role in increasing the genetic risk to positive 
symptoms of psychosis in a proportion of LOAD families 
[85]. However, these results are controversial, since a 
different study [90] found no correlation between NRG-
1 variants and delusions, hallucinations, psychosis, or 
elation/mania in an AD cohort. Further investigations 
are required, and large longitudinal patient cohorts 
should be used.
Neuregulin and Infectious Diseases
Malaria, caused by Plasmodium (with P. falciparum 
being the deadliest), is a devastating infectious disease 
causing approximately 207 million cases worldwide and 
627,000 deaths a year, mainly in children under 5 years 
of age living in sub-Saharan Africa, [91]. In the tropho-
zoite-stage, intra erythrocyte (RBC) parasite proteins are 
transferred to the surface of the RBC where they play 
a role in adherence to the host’s endothelium [92,93], 
destruction of RBC’s and release of cytotoxic heme moi-
eties into circulation which together with interactions 
with host cells [94,95] mediate severity of the disease.
Approximately 1% of P. falciparum infections results 
in cerebral malaria (CM), a brain encephalopathy asso-
ciated with malaria especially in children [91]. In adults 
in South-East Asia, CM accounts for 50% of the malaria 
deaths, as they not only suffer from encephalitis, but 
also have multiple organ failure [96]. CM is clinically de-
fined as having P. falciparum parasitemia and unarous-
able coma, ruling out any other causes, such as menin-
gitis.
Recently there has been an awareness of the burden 
of varying neurological deficit in survivors [97]. CM-re-
lated neurological sequelae are more severe in children 
than in adults. Children living in Africa with severe neu-
rological sequelae often die within a few months of dis-
charge [98]. In adults, coma depth and duration along 
with multiple convulsions are independent risk factors 
for neurological sequelae [98]. These include cranial 
nerve lesions, neuropathies, and extrapyramidal disor-
ders [99].
The pathogenic mechanisms leading to fatal human 
CM are multifactorial and involve alterations in cytokine 
and chemokine expression, localized inflammation and 
microvascular injury that results in the loss of blood 
brain barrier (BBB) integrity. Two hypotheses have been 
proposed to explain dysfunction of the BBB and mortali-
ty associated with CM [100]. First, the sequestration hy-
pothesis, proposes that infected red blood cells (iRBCs) 
bind to endothelial cells and accumulate within brain 
microvessels [101-103] obstructing blood flow, result-
ing in low tissue perfusion, compromised oxygenation 
cognitive abilities and functions, which corroborates a 
potential role of neuroinflammation [84]. Macrophages, 
or microglia, located in the brain, become activated in 
response to any kind of damage, leading to inflamma-
tion [81]. Inflammation is responsible for influencing 
the shaping process of synaptogenesis (the formation 
of new synapses) and the overall reduction of neurons 
[81]. The link between dysfunctions, cognitive impair-
ment, medical comorbidity and premature mortality 
seen in BD patients can be explained by immune system 
signaling the microglia [81]. In both BD and SZ studies, 
NRG-1 deficiency has resulted in behavioral deficits such 
as working memory impairments in both disorders [74]. 
There has been much overlap in the diagnosis of BD and 
SZ because of the similarity they have. Research has 
found that over 50% of those diagnosed with BD have 
some other kind of comorbidity [81-84], which makes 
the differentiation between BD and SZ difficult for clini-
cians. The biggest difference found between the two ND 
is in regard to the neuropsychological deficits and the 
time at which they present themselves: SZ individuals 
exhibit dysfunction preceding the onset of the illness, 
which becomes greater during the first few years of be-
ing diagnosed, while BD patients show cognitive devel-
opment pre-morbidly and demonstrate first episodes 
that are extremely intense [84]. These key differences 
of the timing of the presentation of symptoms have 
been likened role of inflammation in BD and SZ [85], 
along with abnormal sequences and patterns of NRG-1 
and other proteins. A study suggested that NRG-1 defi-
ciency regulates microglial cells that are stress induced 
[74]. Thus, NRG-1 could be used as treatment because 
of its anti-inflammatory properties.
Alzheimer’s disease: Studies on Alzheimer’s disease 
(AD) have shown that neuroinflammation plays a role 
in this disease [12,86,87], thus NRG-1 is considered a 
candidate for its treatment [6]. NRG-1 is responsible 
for creating extremely complex networks of signaling 
proteins with many differing expressions and divergent 
functions during the development of an adult nervous 
system [86]. During inflammation, these proteins alter 
their function. Incorrect or low expression of these pro-
teins lead to manifestation of AD symptoms [74]. NRG-
1 deficiencies have been shown to provide evidence 
for the neuropathology of psychosis [85]. In AD brains, 
ErbB4 immunoreactivity was shown to colocalize with 
apoptotic Bax signal in apoptotic hippocampal neurons. 
Thus, the upregulation of immunoreactivity of NRG-1 
receptor ErbB4, may be involved in AD progression [32]. 
Another study showed that NRG-1 upregulated the ex-
pression of anti-apoptotic protein Bcl-2, demonstrating 
the neuroprotective potential of NRG-1 in AD [88]. The 
soluble NRG-1 plasma levels were significantly higher in 
mild and moderate AD patients compared to control pa-
tients, indicating that NRG-1 could be used as a marker 
for early diagnosis of AD [89]. Due to its localization in 
the brain areas relating to auditory and visual hallucina-
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ing levels of NRG-1β [107]. Indeed, intravenous infusion 
of NRG-1 at onset of ECM attenuated ECM mortality by 
stimulating a robust anti-inflammatory response, while 
reducing pro-inflammatory factors. Also noted was the 
reduction of accumulation of infected erythrocytes in 
brain microvessels, reduction of brain tissue damage, 
and reduction of total mortality.
We recently showed that NRG-1 protects human 
brain microvascular endothelial cells (hCMEC/D3) and 
astrocytes from cell death induced by CXCL10 and heme 
(a cytotoxic by product released by damaged infected 
and non-infected erythrocytes) in vitro [21,22] In ad-
dition, NRG-1 improved heme-disrupted BBB integrity 
in an in vitro BBB model consisting of hCMEC/D3 and 
human astrocytes. In the, cortex and hippocampus of 
mice with advanced stages of ECM, the ErbB4 protein 
is inactivated through dephosphorylation, indicating a 
diffuse distribution in regions of tissue injury. However, 
exogenous infusion of NRG-1 increased phosphorylated 
ErbB4 levels in the cortex and hippocampus of infect-
ed mice; this subsequently reduced STAT3 activation (a 
typical pathogenic pathway in CM) and increased AKT 
activation. These findings were consistent with Lok’s re-
port [108] which showed that NRG-1 increases pAKT in 
order to enhance in vitro survival of endothelial cells. 
Overall, it seems that NRG-1 protects against apoptosis 
and cell death of two major BBB components, human 
brain microvascular endothelial cells and astrocytes 
(Figure 2). Thus, NRG-1 attenuates mortality associated 
and brain tissue damage. Second, the immunopatho-
logical “cytokine” hypothesis, suggests that an exagger-
ated host immune response to Plasmodium infection 
and the adherence of parasitized erythrocytes to endo-
thelial cells promotes the release of pro-inflammatory 
mediators and other cytotoxic molecules responsible 
for compromising BBB cellular components, resulting in 
edema, access of toxins to sensitive brain tissue, neuro-
nal cell damage, coma and death [104-106]. However, 
pathogenesis of CM has not been shown to be exclusive 
to any one hypothesis but involves a combination of 
pathophysiological features, including parasite seques-
tration in the brain, metabolic disturbances and host 
inflammatory responses that mediate CM pathogenesis 
[104-106]. 
There are pathophysiological similarities between 
CM, acute ischemia syndrome (AIS) and TBI, including 
an exaggerated host expression of pro-inflammatory 
factors. This inflammatory response leads to increased 
microvascular endothelial activation with upregulation 
of adhesion molecules, glial activation, focal inflamma-
tion and activation of apoptotic pathways, which can 
eventually lead to brain damage, coma, and death. Rec-
ognizing fundamental similarities shared by CM patho-
genesis and both AIS and TBI, an experimental cerebral 
malaria (ECM) model (Plasmodium berghei ANKA in 
C57BL/6 mice) was used for the first time to investigate 
the role of NRG-1 in ECM prognosis. The results indicat-
ed that ECM was associated with depletion in circulat-
Figure 2: Proposed model demonstrating protective role of NRG1 against cerebral malaria (CM) pathogenesis. During CM 
pathogenesis, some P. falciparum-infected erythrocytes (pRBC) lyse and release heme while others bind to brain vascular 
endothelial cells via adhesion molecules (ICAM, VCAM, etc) causing capillary obstruction and activation of endothelial cells 
as well as release of pro-inflammatory and angiostatic factors such as CXCL10 and activation of STAT3 (1). Downstream of 
the capillary obstruction, endothelial cells, astrocytes, microglia and neurons located in the penumbra are at risk of undergoing 
apoptosis which results in increased permeability of BBB (2) due to dead and dying cells in irreversibly damaged brain tissue 
regions (3). After administration of adequate amounts of NRG-1, cells in the penumbra can be rescued from apoptosis.  It is 
proposed that this might be the basis for effective attenuation of mortality and associated neurological sequelae in patients 
with CM (4). 
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morphological structures of nerve cells were ameliorat-
ed, the integrity of the BBB was restored, and infarct 
volume was reduced. At the same time, neurological 
function was significantly recovered [114]. Cimagler-
min (NRG-1β) treatment significantly enhanced recov-
ery after stroke, inducing axonal sprouting and synapse 
formation. These data suggested that Cimaglermin 
represents a potential candidate for stroke treatment 
[115].
Because of its critical contribution, BBB integrity is a 
key potential therapeutic target in the treatment of the 
acute phase of brain trauma. A study was carried out 
in which mice were subjected to controlled cortical im-
pact (CCI) under anesthesia and BBB permeability was 
assessed by measuring Evans blue dye extravasation 
[86]. NRG-1 was administered intravenously for 10 min-
utes following trauma and Evans blue dye extravasa-
tion decreased by 35% 2 hours post trauma. The results 
showed that NRG-1 decreases BBB injury in a model of 
TBI. This data provides evidence that NRG-1 has a ben-
eficial effect on the barrier function of the brain’s mi-
crovasculature following trauma. These various studies 
demonstrate NRG-1’s potential role in the therapeutic 
strategies for traumatic brain injury. Currently, NRG-1 
is undergoing clinical trials for use against TBI (Clinical-
Trails.gov NCT01258387 and NCT01944683).
In a rat model of Charcot-Marie-Tooth neuropathy, 
early NRG-1 treatment promoted Schwann cell differ-
entiation, preserved axons and restored nerve function 
[116]. In a mouse model of spared nerve injury, NRG-1 
inhibited neuropathic pain in a dose-dependent man-
ner. However, in a formalin-induced pain model, NRG-1 
was found to aggravate pain. These findings may pro-
vide different approaches for neuropathic pain in differ-
ent injury types [117]. Conversely, monoclonal antibody 
Herceptin (Trastuzumab) blocked NRG receptor ErbB2 
and increased axonal regeneration in a rat model of 
acute or chronic nerve injury. However, these effects 
were independent from NRG pathway. These results 
raise the possibility of using targeted therapies to im-
prove outcomes of peripheral nerve injury [118].
NRG-1 could potentially significantly increase the ef-
fectiveness of current anti-malarial therapy against hu-
man CM. Despite appropriate anti-malarial treatment, 
mortality associated with CM remain as high as 30% 
while up to 20% of survivors experience neurological 
complications [96]. Thus, anti-malarial drugs are clear-
ly not adequate for saving lives of CM non-survivors 
and adjunctive therapy is needed. Adjunctive therapy 
has been proposed based on pathophysiology studies 
conducted with murine ECM. The purpose of these ad-
junctive therapies were to shorten coma and decrease 
fatality as well reduction in the rate and severity of neu-
rological sequelae [98]. Some of these therapies have 
been deleterious but others are currently being ex-
plored, NRG-1 being one of them.
with CM through activation of ErbB4/AKT and inactiva-
tion of STAT3 signaling pathways. These findings sug-
gest that adjunctively augmenting NRG-1 during ECM 
therapy may be an effective therapeutic approach to 
reduce CM-induced CNS tissue injury. To date no oth-
er studies with other infectious diseases such as Zika, 
toxoplasmosis, HIV/AIDS and others with reported del-
eterious effects on the CNS has been reported. It will 
be interesting to determine whether NRG will attenuate 
the CNS injury associated with these diseases and their 
respective neuropathologies or sequelae.
Neuregulin: Drug or Target?
Animal studies have shown that myocardial NRG-1 is 
activated in response to ischemia. Furthermore, when 
NRG-1β is used as treatment in animal models of car-
diac failure, studies have shown that it improves heart 
function [109]. In an in vitro study, NRG-1β treatment 
within the period of deoxygenation and glucose depri-
vation, significantly increased oligodendrocyte type2 
astrocytes progenitor’s survival and decreased apop-
tosis [110]. There is also concern that NRG treatment 
might exert “off-target” effects by nature of its mito-
genic properties as a growth factor, and the well-es-
tablished role of ErbB2 as an oncogene in a variety of 
malignancies. To address this issue, a bivalent version 
of NRG was engineered to preferentially target ErbB4 
homodimer activation, thereby preventing doxorubi-
cin-induced cardiomyocyte death without activating 
or potentiating cancer cell signaling [76,78]. Further 
studies are clearly warranted to determine whether 
this or other modified ligands, or alternative delivery 
methods are needed to increase the therapeutic win-
dow for NRG [111]. When NRG-1 was administered for 
10 days in patients with heart failure, it improved car-
diac function when patients were evaluated after 30 
days (ChiCTR-TRC-00000414) [44]. When NRG-1 was in-
fused for 11 days, cardiac function was improved for 12 
weeks (Australian New Zealand Clinical Trials Registry, 
anzctr.org.au Identifier: ACTRN12607000330448) [112]. 
Currently, clinical trials that use NRG-1 in heart fail-
ure are: NCT01214096, NCT01439789, NCT01439893, 
NCT01251406, NCT03388593, but no results have been 
yet posted.
NRG-1 has neuroprotective effects against ischemic 
stroke. Studies suggest that there is a therapeutic win-
dow of opportunity between the onset of ischemia and 
irreversible neuronal death and that irreversible inju-
ry is not complete until about 6 hours after ischemia 
[113]. However, if a single bolus injection of NRG-1 was 
administered at either 0, 4 or 12 hours after reperfu-
sion following middle cerebral artery occlusion [113], 
a significant decrease in the subcortical and cortical le-
sions in NRG-1 treated rats was shown. These results 
contribute to NRG-1’s potential use in therapy in focal 
cerebral ischemia. When NRG-1β was administered, the 
ischemia-induced apoptosis decreased, the abnormal 
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maintenance, as well as in many disorders. However, 
the functions of NRG-1 and the pathways it mediates 
are not completely understood; Figure 3 shows pro-
posed NRG-1 pathways. In animal models, homozygous 
deletion of the NRG-1 gene is devastating, leading to 
death in utero, overexpression of NRG-1 impacts neg-
atively on various cognitive and behavioral processes, 
suggesting that further investigations are necessary to 
determine the NRG-1 dose that is ultimately beneficial 
for patients.
Although NRG-1 plays a protective role during devel-
opment and adult life, its effects in disease vary. NRG-1 
improves cardiac function in patients with chronic heart 
failure and increases tissue viability and angiogenesis in 
animal models of heart ischemia. Furthermore, NRG-1 is 
neuroprotective during episodes of brain ischemia and 
injury, as well as in AD. Its elevated plasma levels in pa-
tients with mild or moderate AD suggests that NRG-1 
can be used as a marker for early diagnosis. However, 
the role of NRG-1 in cognitive disorders remains to be 
fully understood. In ECM, we demonstrated that NRG-
1 circulating levels diminished, while its infusion led to 
a reduced mortality due to a strong anti-inflammato-
ry response and a reduction of parasitic RBC accumu-
lation in microvessels and decreased tissue damage. 
Furthermore, we showed that NRG-1 protects brain 
Evidence from genetic, transgenic and post-mortem 
studies have strongly suggested that altered NRG-1/
ErbB4 signaling is involved in SZ susceptibility. NRG-1/
ErbB4 signaling has interactions with GABAergic, gluta-
matergic and dopaminergic neurotransmissions that are 
involved in SZ. Identifying the targets in NRG-1/ErbB4 
signaling and interactive pathways will provide oppor-
tunity for development of antipsychotics with specific 
efficacy and fewer side effects [119].
Neuregulin can be used as treatment in other dis-
eases. Neuregulin regulates glucose and lipid homeo-
stasis. An engineered fusion protein using NRG-1 and 
Fc domain of human IgG1 (NRG1-Fc) exhibits extended 
half-life in circulation and improved potency in recep-
tor signaling. NRG1-Fc treatment lowered blood glu-
cose, improved insulin sensitivity and suppressed food 
intake in obese mice [120]. In a different study, NRG-1 
treatments improved glucose tolerance in Db/Db mice, 
through inhibition of hepatic gluconeogenesis [121].
Neuregulin Signaling Blockade in Cancer
Studies have shown that in lung cancer animal mod-
els, inhibition of NRG-1 signaling leads to reduced tu-
mor growth and enhanced intensity and duration of the 
response to chemotherapy [122]. Furthermore, clinical 
trials especially used drugs that targeted the ErbB (HER) 
receptors. In a Phase IV clinical trial that enrolled pa-
tients with advanced HER+ carcinomas, Lumretuzumab 
(anti-HER3 monoclonal antibody) was used in combina-
tion with EGFR-blocking agent Erlotinib or Cetuximab. 
The toxicity of those drugs was manageable, but there 
was no evidence of meaningful clinical benefit [123]. 
However, Duligotuzumab, a dual-action antibody that 
blocks ligand binding to human HER3 and EGFR, in com-
bination with chemotherapy (Cisplatin-5-Fluorouracil or 
Carboplatin-Paclitaxel) was used for patients with recur-
rent or metastatic squamous cell cancer of the head and 
neck. This treatment combination showed encouraging 
activity, 67% of the patients confirming partial or com-
plete response [124].
Clinical trials targeting NRG pathways in cancer use 
MM-121 (antibody targeting ErbB3) in combination 
with chemotherapy in Heregulin-positive non-small cell 
lung cancer (NCT02387216). A Phase 2 trial of MM-141 
(antibody against Her3 and IGF-1) and Nab-paclitaxel 
and Gemcitabine in pancreatic cancer is active, but not 
recruiting yet (NCT02399137). In ovarian cancer, study 
#NCT01447706 tried to determine whether the combi-
nation of MM-121 and paclitaxel has better results than 
paclitaxel alone. Results showed that overall survival 
was 13.7 months for Pax + MM141 compared to Pax 
alone (10.17 months). In cancer, targeting NRG pathway 
seem to improve survival and prognosis.
Conclusions
Studies have shown the importance of NRG and its 
corresponding receptors in organ development and 
Figure 3: Proposed Neuregulin-1 Pathways. The ligand in-
teraction with ErbB 1,3, and 4 increases their affinity and 
induces heterodimerization of ErbB1-4, activating the tyro-
sine kinase domain. This allows the cytoplasmic region of 
the ErbB to become phosphorylated. The phosphorylated 
tyrosine residues recruit various adaptors/effectors that in-
duce intracellular signals leading to the survival of the cell 
by lowering apoptosis, inflammation, edema, and ultimately 
restoring BBB function. 
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